NCT04257994 Distribution of Cell-cell Junction Proteins in Arrhythmic Disorders
| NCT ID | NCT04257994 |
| Status | Recruiting |
| Phase | — |
| Sponsor | St. George's Hospital, London |
| Condition | Arrhythmogenic Right Ventricular Dysplasia |
| Study Type | OBSERVATIONAL |
| Enrollment | 26 participants |
| Start Date | 2017-10-15 |
| Primary Completion | 2024-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 26 participants in total. It began in 2017-10-15 with a primary completion date of 2024-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Every week in the UK, 12 apparently healthy and fit individuals under the age of 35 die suddenly, a tragic event known as sudden cardiac death (SCD). The investigators have shown that heritable cardiac disorders affect the distribution of proteins at the cardiac cell-cell junctions, the areas where cardiac cells are mechanically and electrically coupled. This knowledge has helped the investigators diagnose specific heart disorders in individuals thus reducing the risk and incidence of SCD. Yet, the primary material required is a heart sample. A heart biopsy is an invasive process that comes with risks and is not performed unless absolutely necessary. And it is impossible to obtain a heart sample from an individual that may be carrying a disease-causing mutation (and hence be at risk of SCD) but does not yet show evidence of disease manifestation. The investigators recently showed that buccal cells show changes in protein distribution equivalent to those exhibited by the heart,hence providing them with a surrogate tissue for the myocardium. The investigators aim to use buccal smears as a means to identify those at risk of SCD. Patients regularly seen at the cardiology clinics at St. George's Hospital can participate in the study. The investigators shall take a buccal smear simply by rubbing a soft brush at the inside of their cheek and smearing it on a slide. Most individuals willing to participate in the study will only have to provide the investigators with a sample once. However, in selected cases (for instance, if the patients show disease progression or have a change in medication) they may be asked to provide the investigators with a subsequent sample during one of their scheduled follow-up visits. The process takes only a few seconds, is totally risk- and pain-free and it is anticipated to have great implications in diagnosis and patient management.
Eligibility Criteria
Inclusion Criteria:• Participants will include patients diagnosed with a heritable arrhythmic disorder (including arrhythmogenic, hypertrophic and dilated cardiomyopathy, cardiac sarcoidosis as well as cardiac channelopathies; Long QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia) followed at the Inherited Cardiac Conditions (ICC) service of St. George's University Hospitals NHS Foundation Trust. * Family members of victims of SCD evaluated at the same clinic for risk assessment and diagnosis. These groups include both individuals with clear disease manifestation (termed "affected") as shown by conventional diagnostic approaches (electrocardiography, echocardiography, cardiac MRI, Holter monitoring) as well as potential carriers of disease-causing mutations who, however, may not/not yet manifest any overt sign of cardiovascular abnormalities (termed "carriers"). These are typically family members of probands diagnosed with a heritable arrhythmic disorder or family members of a sudden cardiac death victim. * All individuals that fall in the above categories will be included regardless of their management (medication, devices, and surgical procedures). * Individuals with co-existing conditions will also be included and their medical history will be taken into account when interpreting the results of the immunohistochemical analysis. * Adult individuals (\>18 years of age). * Pregnant women will be included as the approach used is not in any way harmful or uncomfortable. * All individuals must have provided the study team with a signed informed consent in order to participate in the study. Exclusion Criteria:• Children under 18 years of age * Individuals lacking decisional capacity. * Individuals with non-heritable, non-arrhythmic cardiac disorders (such as ischemic heart disease or inflammatory disorders) followed at St. George's University Hospitals NHS Foundation Trust. * Non-English speakers will be excluded from the study unless a translator is present who can thoroughly explain to them the research question/plan in order for them to provide an informed consent.
Contact & Investigator
Angeliki Asimaki
PRINCIPAL INVESTIGATOR
St George's, University of London
Frequently Asked Questions
Who can join the NCT04257994 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Arrhythmogenic Right Ventricular Dysplasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04257994 currently recruiting?
Yes, NCT04257994 is actively recruiting participants. Contact the research team at aasimaki@sgul.ac.uk for enrollment information.
Where is the NCT04257994 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT04257994 clinical trial?
NCT04257994 is sponsored by St. George's Hospital, London. The principal investigator is Angeliki Asimaki at St George's, University of London. The trial plans to enroll 26 participants.